Global life sciences companies should no longer view Saudi Arabia only as a market for selling products. The country is using platforms backed by the Public Investment Fund (PIF), Saudi Arabia’s sovereign wealth fund, together with government procurement and foreign technology partnerships to build local capability in selected parts of the healthcare sector.
Saudi Arabia’s policy objective is to reduce import dependence, improve supply security and support local manufacturing, while bringing in foreign technology, using procurement leverage and eventually creating a platform for regional exports. This should not be viewed only as a healthcare reform story. It is also an industrial policy story.
For global life sciences companies, this creates openings beyond traditional sales and distribution. For the right companies, Saudi Arabia may become relevant as a place to manufacture, license technology, co-develop products, transfer know-how, run clinical programmes, deploy digital health platforms or form joint ventures with Saudi partners.
Why this matters now
Saudi Arabia’s life sciences localisation agenda is moving from policy direction to implementation. PIF-backed platforms are supporting local manufacturing, biopharma capacity, vaccines, chronic disease therapies, genomics and healthcare data. At the same time, government procurement is becoming an important driver of market access and localisation strategy.
This is an important moment for global life sciences companies to assess whether Saudi Arabia should be part of their market access, manufacturing, technology transfer, clinical, digital health or regional growth strategy.
Procurement as a market driver
Government and government-linked procurement is a major part of the Saudi healthcare market. In life sciences, public-sector demand is not only a route to sales. It is also a policy tool that can support supply security, local content and domestic capability.
This is particularly important in healthcare, where government hospitals, public healthcare institutions and national procurement platforms can influence market access, pricing, supply expectations and long-term commercial strategy. The National Unified Procurement Company, commonly known as Nupco, is the national procurement and logistics platform for pharmaceuticals, medical devices and medical supplies. It is central to this landscape.
For global life sciences companies, procurement strategy should be considered early. Companies whose products are important to Saudi public-sector healthcare demand may need to assess whether a conventional export or distributor model is sufficient, or whether a Saudi partner, local manufacturing arrangement, technology transfer structure or Saudi joint venture may be commercially or strategically preferable.
The procurement angle also affects legal planning. It can influence product registration, tender qualification, pricing, supply commitments, local content positioning, warehousing, logistics, distribution arrangements and whether the company needs a real local operating presence in Saudi Arabia.
Lifera and the localisation agenda
Saudi Arabia’s current focus is not broad early-stage drug discovery. It is focused on products and capabilities that matter directly to public health, supply security and government healthcare demand. The main areas include critical medicines, local biopharma manufacturing, contract development and manufacturing services, vaccines, biologics, biosimilars, insulin and other chronic disease therapies, genomics and multiomic testing, procurement and logistics infrastructure, digital health and artificial intelligence-enabled healthcare platforms.
Lifera, launched in 2023 as a wholly owned PIF pharmaceutical manufacturing company, is the clearest example of this shift. Its role is to help Saudi Arabia move from reliance on imported high-priority medicines toward local manufacturing, technology transfer and domestic biopharma capability.
Lifera is intended to operate as a Saudi localisation platform, not as a passive financial investor. For global life sciences companies, this matters because Lifera-type structures may involve contract manufacturing, process transfer, product localisation, training, quality systems, supply commitments and long-term commercial arrangements with Saudi counterparties.
Contract development and manufacturing services are also central to this strategy. In this context, they mean more than factory capacity. They include regulated manufacturing, process development, quality control, validation, packaging, documentation and the operational systems needed to produce pharmaceutical products in a compliant and commercially reliable way.
The model is straightforward. The Saudi side can bring capital, market access, procurement access and policy support. The international partner brings products, technology, manufacturing know-how, quality systems, training and regulatory experience. The legal and commercial challenge is to define those contributions clearly, protect intellectual property and know-how, allocate regulatory responsibility and set out the parties’ long-term supply and manufacturing obligations.
What recent transactions show
Recent public transactions show how this policy is being implemented. They include the acquisition of a Saudi biomanufacturing company to support local insulin and chronic disease therapy manufacturing, vaccine manufacturing arrangements involving a Saudi manufacturing platform, a global vaccine technology provider and a regional distribution group, and a genomics and multiomics joint venture with an international diagnostics and data company.
Other announced or emerging arrangements point to biologics, biosimilars, glucagon-like peptide-1 therapies, commonly referred to as GLP-1 therapies, and vaccine localisation. These examples suggest that Saudi Arabia is prioritising areas where there is strong domestic demand, import dependence, public health relevance and a realistic path toward local production or local service delivery.
The common thread is not simply investment. It is the combination of foreign technology, local manufacturing, workforce development, procurement alignment and long-term supply resilience.
For global life sciences companies, the implication is practical. A conventional export or distributor model may still work for some products, but it may not be sufficient for products that are strategically important to Saudi healthcare demand. Companies with relevant products, platforms or manufacturing capabilities should consider whether Saudi Arabia requires a deeper structure, such as a Saudi partner, local operating entity, joint venture, contract manufacturing arrangement, licensing model or technology transfer structure.
Where opportunities may emerge
Saudi Arabia’s life sciences sector is still developing. That means the market is not limited to large pharmaceutical companies with finished products. It also extends to companies that can help build the manufacturing, regulatory, clinical, data and logistics infrastructure needed to support a larger life sciences sector.
Relevant companies may include diagnostics providers, genomics platforms, contract development and manufacturing organisations, clinical research organisations, medtech companies, artificial intelligence health companies, vaccine technology providers, quality systems and Good Manufacturing Practice specialists, cold chain and healthcare logistics providers, healthcare software companies and data platform providers.
For these companies, the Saudi opportunity may not be a single transaction. It may begin with market access, product registration or procurement support, then move into a local partner arrangement, joint venture, manufacturing structure, technology transfer model or regional platform. The longer-term opportunity is to use Saudi Arabia as a base for serving the Saudi market first, and potentially the Gulf Cooperation Council countries or the wider Middle East and North Africa region over time.
How companies should assess the opportunity
Global life sciences companies assessing Saudi Arabia should start with a practical question. Is Saudi Arabia only a sales market for the company, or could it also become part of its localisation, manufacturing, technology transfer, clinical, digital health or regional growth strategy? The answer will depend on the product, the procurement route, the role of Saudi government or government-linked buyers, the need for local content and whether the company’s technology or manufacturing capability matches Saudi Arabia’s localisation priorities.
A focused assessment should cover four areas.
First, companies should assess the product and market pathway. This includes whether the product or platform is relevant to Saudi public-sector healthcare demand, whether approval from the Saudi Food and Drug Authority is required, whether clinical trials or ethics approvals may be needed and whether the current export or distributor model is sufficient.
Second, companies should assess the most appropriate Saudi structure. Depending on the opportunity, this may involve a Saudi partner, licensed operating entity, joint venture, contract manufacturing arrangement, technology transfer structure or contract development and manufacturing organisation model. Regional headquarters considerations may also need to be assessed where government-facing business is material.
Third, companies should assess the operational and regulatory requirements. These may include product registration, Good Manufacturing Practice compliance, pharmacovigilance, import controls, storage, cold chain, distribution, local content, tender qualification and supply commitments.
Fourth, companies should assess the commercial and legal protections needed for a long-term Saudi arrangement. These may include intellectual property ownership, licensing, know-how protection, data governance, health data, compliance with Saudi Arabia’s Personal Data Protection Law, cybersecurity, cloud hosting, artificial intelligence deployment, tax, transfer pricing, employment and Saudisation.
In many cases, companies should also plan early for engagement with relevant Saudi governmental and government-linked bodies, including regulators, procurement platforms and investment authorities. This engagement should be structured carefully, aligned with the company’s market entry and localisation strategy and supported by clear legal, regulatory and commercial messaging.
The legal framework matters because Saudi localisation arrangements often involve several overlapping workstreams. A Saudi life sciences opportunity may begin as a market access or procurement question, but quickly become a foreign investment, joint venture, regulatory, intellectual property, technology transfer, data, tax, employment and government engagement matter.
How Bird & Bird can help
Bird & Bird helps life sciences, healthcare, technology and digital health companies assess and structure Saudi-facing opportunities. Our Saudi and international teams work together to address the Saudi legal framework and the cross-border commercial, regulatory, intellectual property and technology issues that commonly arise in life sciences transactions.
We advise on Saudi market entry and transaction structuring, including foreign investment licensing, Saudi entity establishment, joint ventures, shareholder arrangements, governance protections, reserved matters and exit planning.
We support localisation, manufacturing and technology transfer arrangements, including contract development and manufacturing organisation structures, licensing, know-how protection, manufacturing commitments, quality obligations, supply arrangements and long-term partnership documentation.
We also advise on procurement, local content and regulatory planning. This includes government and government-linked procurement routes, tender qualification, supply commitments, distribution arrangements, commercial agency issues, Saudi Food and Drug Authority-related structuring, Good Manufacturing Practice compliance, pharmacovigilance, clinical trials, import controls, storage, cold chain and post-market obligations.
For digital health and data-driven opportunities, we assist with intellectual property, health data, compliance with Saudi Arabia’s Personal Data Protection Law, cybersecurity, cloud hosting, artificial intelligence-enabled healthcare platforms, digital health solutions and healthcare software deployment.
Our Team
For further information on Saudi life sciences localisation, market entry, procurement, technology transfer and joint venture opportunities, please contact Raya Alkhatib and Peter Koh.
Get in touch
Saudi Arabia’s life sciences strategy has a clear direction, but the sector is still developing. For companies with relevant products, technology, manufacturing know-how, data capabilities or healthcare platforms, Saudi Arabia may be relevant not only as a sales market, but as a localisation, manufacturing and partnership platform. The opportunity requires early planning, careful structuring and a clear understanding of Saudi Arabia’s legal, regulatory and procurement environment.
If you are assessing market entry, procurement exposure, localisation, manufacturing, technology transfer, clinical, digital health or Saudi partnership opportunities, we would welcome the opportunity to discuss how Saudi Arabia’s life sciences strategy may affect your business and how we may be able to assist.
For further information, please contact:
Raya Alkhatib, Partner, Bird & Bird
raya.alkhatib@twobirds.com
